相关实验视频

Updated: Jan 11, 2026

Surgical Approach and Complications of Stand-alone Lateral Trans-Psoas Interbody Fusion

Surgical Approach and Complications of Stand-alone Lateral Trans-Psoas Interbody Fusion

Published on: February 14, 2025

对肥胖关节置换患者并发症解决率的分析

Austin Schwartz¹, Nicholas Brown, Michael Wesolowski

¹From the Loyola University Chicago Stritch School of Medicine (Dr. Schwartz); the Department of Orthopaedic Surgery and Rehabilitation, Loyola University Medical Center (Dr. Brown); and the Department of Statistics and Clinical Research, Loyola University Medical Center (Mr. Wesolowski), Maywood, IL.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews

|November 11, 2025

概括

在BMI>40的关节置换手术患者中观察到高并发症率,但大多数患者在90天内可治疗. 身体质量指数在这个队列中没有显著影响并发症率.

科学领域:

整形外科手术整形外科手术
肥胖医学肥胖医学
手术结果研究研究.

背景情况:

体重指数 (BMI) 是关节置换手术的关键因素,因为并发症风险很高.
对于接受关节置换的BMI升高患者并发症的可治疗性,数据有限.
这项研究量化了BMI> 40.0的患者在90天内可治疗的并发症.

研究的目的:

为了确定BMI>40接受关节置换的患者的发病率和并发症类型.
评估90天内这些并发症的可治疗性和解决率.
评估BMI对全膝关节整形术 (TKA) 和全关节整形术 (THA) 的并发症率的影响.

主要方法:

对700名BMI>40的患者进行回顾性审查,接受TKA (n=475) 或THA (n=225).
对人口统计,并发症,外科手术期间变量和并发症的分析.
使用通用线性混合模型 (GLMMs) 来控制共变量.

主要成果:

700名患者中有211名患者 (30.1%) 经历了至少一个并发症.
医学并发症发生在29.3%,手术并发症发生在15.0%,重复手术发生在13.9%,再入院发生在14.9%.
70.7%的并发症是可治疗的;BMI没有显著影响关节或膝关节置换中的并发症率,BMI分层也没有.

结论:

接受关节置换的BMI>40患者的并发症率很高,通常与并发症有关.
大多数观察到的并发症是可以治疗的,并在90天内消失.
体重指数本身并不是这个患者群体中并发症率的重要预测因素.

更多相关视频

Optimizing Minimally Invasive Spine Surgery: A Fully 3D CT O-Arm Navigated Workflow in MIS TLIF

Optimizing Minimally Invasive Spine Surgery: A Fully 3D CT O-Arm Navigated Workflow in MIS TLIF

Published on: October 17, 2025

$Autologous Microfractured and Purified Adipose Tissue for Arthroscopic Management of Osteochondral Lesions of the Talus$ 07:24

Autologous Microfractured and Purified Adipose Tissue for Arthroscopic Management of Osteochondral Lesions of the Talus

Published on: January 23, 2018

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...